SCHEMBL703165

SCHEMBL703165

CS(=O)(=O)c1cnc(NC(=O)c2cccc(O)c2)s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 1/20 0.51
HSD17B2 P37059 1/20 0.51
KDR P35968 1/20 0.48
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAPT P10636 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
THRB P10828 1/20 0.46
MAPK9 P45984 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CCNE1 P24864 1/20 0.45
CDK2 P24941 1/20 0.45
CDK5 Q00535 1/20 0.45
FFAR2 O15552 1/20 0.45
STAT3 P40763 1/20 0.45
SCD O00767 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4756952 0.88 RAB9A (0.57) KDRMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL4756954 0.87 FFAR2 (0.46) HSD17B1KDRMEN1KMT2ASMN1; SMN2
SCHEMBL4757983 0.85 KDR (0.61) KDRMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL703520 0.84 FFAR2 (0.48) KDRMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL4755961 0.83 NPC1 (0.48) KDRMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL703471 0.82 MEN1 (0.51) KDRMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL23934151 0.82 NPC1 (0.50) KDRMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL4757111 0.81 MEN1 (0.47) MEN1KMT2ASMN1; SMN2MAPTNPC1
SCHEMBL4757155 0.79 NPC1 (0.59) KDRMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL4757105 0.79 FFAR2 (0.44) MEN1KMT2ASMN1; SMN2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11850237-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2023-12-26 US disclosed
US-11850237-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2023-12-26 US disclosed
EP-2445349-B1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES LC (US) 2022-02-09 EP disclosed
EP-3895706-A1 THIAZOLINIDE COMPOUNDS FOR TREATING NON-INFLUENZA VIRAL INFECTIONS Romark Laboratories, L.C. (US) 2021-10-20 EP disclosed
US-20210177809-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2021-06-17 US disclosed
US-10912768-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2021-02-09 US disclosed
US-20190307730-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2019-10-10 US disclosed
US-10363243-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2019-07-30 US disclosed
US-20180078533-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2018-03-22 US disclosed
US-20180078533-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2018-03-22 US disclosed
US-8124632-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES, L.C. (US) 2012-02-28 US disclosed
US-20100330173-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. 2010-12-30 US disclosed
US-20100330173-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. 2010-12-30 US disclosed
WO-2010151577-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2010-12-29 WO disclosed
EP-2178852-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS Romark Laboratories, L.C. (US) 2010-04-28 EP disclosed
WO-2009035788-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. (US) 2009-03-19 WO disclosed
WO-2009035788-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. (US) 2009-03-19 WO disclosed
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. 2009-02-05 US disclosed
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. 2009-02-05 US disclosed
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10912768-B2 Compounds and methods for treating influenza HIF1AN, HAVCR2, NEU1 HSD17B1 516/4885HSD17B2 638/4885KDR 4689/4885
US-20180078533-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 HSD17B1 516/4885HSD17B2 638/4885KDR 4689/4885
US-20210177809-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 HSD17B1 516/4885HSD17B2 638/4885KDR 4689/4885
US-20190307730-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 HSD17B1 516/4885HSD17B2 638/4885KDR 4689/4885
US-20100330173-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 HSD17B1 516/4885HSD17B2 638/4885KDR 4689/4885
US-11850237-B2 Compounds and methods for treating influenza HIF1AN, HAVCR2, NEU1 HSD17B1 516/4885HSD17B2 638/4885KDR 4689/4885
US-10363243-B2 Compounds and methods for treating influenza HIF1AN, HAVCR2, NEU1 HSD17B1 516/4885HSD17B2 638/4885KDR 4689/4885
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS HAVCR2, EIF2AK2, AADAC HSD17B1 1606/4885HSD17B2 2340/4885KDR 4456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.